Brief: Aeon Biopharma Completes Enrollment In Phase 2 Trial Of Abp-450 For Preventive Treatment Of Episodic Migraine
21/12/2022 12:37
Dec 21 (Reuters) - Priveterra Acquisition Corp PMGM.O :
* AEON BIOPHARMA COMPLETES ENROLLMENT IN PHASE 2 TRIAL OF
ABP-450
FOR PREVENTIVE TREATMENT OF EPISODIC MIGRAINE
* PRIVETERRA ACQUISITION CORP- TOPLINE DATA EXPECTED TO BE
ANNOUNCED IN 2H 2023
* TOPLINE DATA EXPECTED TO BE ANNOUNCED IN 2H 2023
Source text for Eikon: ID:nGNX1CHTY2
Further company coverage: PMGM.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Aeon Biopharma
See all newsBrief: Aeon Biopharma Reports bpd Type 2A Meeting With FDA And Shareholder Approval Of The November Transactions
Brief: Aeon Biopharma Announces Execution Of Exchange Agreement With Daewoong
Brief: Aeon Biopharma Announces First Closing Of Pipe Investment And Provides Update On FDA Type 2A Meeting Scheduling
Brief: Aeon Biopharma Announces FDA bpd Type 2A Meeting For Abp-450 On November 19
Brief: Aeon Biopharma Announces CEO Transition